{"DataElement":{"publicId":"2987376","version":"1","preferredName":"Malignant Hematologic Disease or Disorder Present Type","preferredDefinition":"A description of the malignant hematologic disease or disorder.","longName":"2987353v1.0:2987373v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2987353","version":"1","preferredName":"Malignant Hematologic Disease or Disorder Present","preferredDefinition":"Refers to abnormal cell activity manifested by decreased control over growth and function, causing tumor growth or spread into surrounding tissue and adverse effects to the host._Pertaining to or related to the blood and blood-forming organs._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Being or existing in a specified place or at the specified time.","longName":"5095333v1.0:2233878v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"5095333","version":"1","preferredName":"Malignant Hematologic Disease or Disorder","preferredDefinition":"Refers to abnormal cell activity manifested by decreased control over growth and function, causing tumor growth or spread into surrounding tissue and adverse effects to the host.:Pertaining to or related to the blood and blood-forming organs.:Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","longName":"C14143:C62780:C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant","conceptCode":"C14143","definition":"Refers to abnormal cell activity manifested by decreased control over growth and function, causing tumor growth or spread into surrounding tissue and adverse effects to the host.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Hematologic","conceptCode":"C62780","definition":"Pertaining to or related to the blood and blood-forming organs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28217233-4EBE-A721-E050-BB89AD430EC3","latestVersionIndicator":"Yes","beginDate":"2015-12-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-30","modifiedBy":"ONEDATA","dateModified":"2015-12-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233878","version":"1","preferredName":"Present","preferredDefinition":"Being or existing in a specified place or at the specified time.","longName":"C25626","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Present","conceptCode":"C25626","definition":"Being or existing in a specified place or at the specified time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F970CDF6-F829-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"ONEDATA","dateModified":"2005-06-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D3C0785-85A4-0279-E040-BB89AD4376C9","latestVersionIndicator":"Yes","beginDate":"2010-01-15","endDate":null,"createdBy":"WHITES","dateCreated":"2010-01-15","modifiedBy":"NYCHM","dateModified":"2016-07-25","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2987373","version":"1","preferredName":"Malignant Hematologic Disease or Disorder Type","preferredDefinition":"Refers to abnormal cell activity manifested by decreased control over growth and function, causing tumor growth or spread into surrounding tissue and adverse effects to the host._Pertaining to or related to the blood and blood-forming organs._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Type; a subdivision of a particular kind of thing.","longName":"2987373v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Acute lymphoblastic leukemia (ALL)","valueDescription":"Acute Lymphoblastic Leukemia","ValueMeaning":{"publicId":"3322383","version":"1","preferredName":"Acute Lymphoblastic Leukemia","longName":"3322383","preferredDefinition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Lymphoblastic Leukemia","conceptCode":"C3167","definition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B36DFA8A-BB5D-6AE7-E040-BB89AD432073","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"25C6CC93-31F9-9598-E050-BB89AD436A4D","beginDate":"2015-11-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-11-30","modifiedBy":"ONEDATA","dateModified":"2015-11-30","deletedIndicator":"No"},{"value":"Non-Hodgkin lymphoma","valueDescription":"Non-Hodgkin Lymphoma","ValueMeaning":{"publicId":"2573076","version":"1","preferredName":"Non-Hodgkin Lymphoma","longName":"2573076","preferredDefinition":"Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Hodgkin Lymphoma","conceptCode":"C3211","definition":"Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EA81-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-09","endDate":null,"createdBy":"KLINGERK","dateCreated":"2005-02-04","modifiedBy":"PWEST","dateModified":"2014-05-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"25C6CC93-322B-9598-E050-BB89AD436A4D","beginDate":"2015-11-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-11-30","modifiedBy":"ONEDATA","dateModified":"2015-11-30","deletedIndicator":"No"},{"value":"Hodgkin lymphoma","valueDescription":"Hodgkin Lymphoma","ValueMeaning":{"publicId":"4981811","version":"1","preferredName":"Hodgkin Lymphoma","longName":"4981811","preferredDefinition":"A lymphoma, previously known as Hodgkin's disease, characterized by the presence of large tumor cells in an abundant admixture of nonneoplastic cells. There are two distinct subtypes: nodular lymphocyte predominant Hodgkin lymphoma and classical Hodgkin lymphoma. Hodgkin lymphoma involves primarily lymph nodes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hodgkin Lymphoma","conceptCode":"C9357","definition":"A lymphoma characterized by the presence of relatively few malignant cells called Reed-Sternberg cells and mononuclear Hodgkin cells that are admixed with nonneoplastic inflammatory cells. The malignant cells have a distinctive immunophenotype; they are positive for CD30 and CD15 and negative for CD3, CD20, and CD45.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E139787-9898-E8CC-E050-BB89AD435F1A","latestVersionIndicator":"Yes","beginDate":"2015-08-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-08-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"25C6CC93-323F-9598-E050-BB89AD436A4D","beginDate":"2015-11-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-11-30","modifiedBy":"ONEDATA","dateModified":"2015-11-30","deletedIndicator":"No"},{"value":"Chronic lymphocytic leukemia","valueDescription":"Chronic Lymphocytic Leukemia","ValueMeaning":{"publicId":"4264837","version":"1","preferredName":"Chronic Lymphocytic Leukemia","longName":"4264837","preferredDefinition":"The most common type of chronic lymphoid leukemia.  It comprises 90% of chronic lymphoid leukemias in the United States.  Morphologically, the neoplastic cells are small, round B-lymphocytes.  This type of leukemia is not considered to be curable with available therapy. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Lymphocytic Leukemia","conceptCode":"C3163","definition":"The most common type of chronic lymphoid leukemia.  It comprises 90% of chronic lymphoid leukemias in the United States.  Morphologically, the neoplastic cells are small, round B-lymphocytes.  This type of leukemia is not considered to be curable with available therapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42EF-FFD5-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"25C6CC93-3249-9598-E050-BB89AD436A4D","beginDate":"2015-11-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-11-30","modifiedBy":"ONEDATA","dateModified":"2015-11-30","deletedIndicator":"No"},{"value":"Other acute leukemia","valueDescription":"Other Acute Leukemia","ValueMeaning":{"publicId":"5057152","version":"1","preferredName":"Other Acute Leukemia","longName":"5057152","preferredDefinition":"Different than the one(s) previously specified or mentioned.: A clonal (malignant) hematopoietic disorder with an acute onset, affecting the bone marrow and the peripheral blood.  The malignant cells show minimal differentiation and are called blasts, either myeloid blasts (myeloblasts) or lymphoid blasts (lymphoblasts).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Acute Leukemia","conceptCode":"C9300","definition":"A clonal (malignant) hematopoietic disorder with an acute onset, affecting the bone marrow and the peripheral blood.  The malignant cells show minimal differentiation and are called blasts, either myeloid blasts (myeloblasts) or lymphoid blasts (lymphoblasts).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"25C6CC93-3253-9598-E050-BB89AD436A4D","latestVersionIndicator":"Yes","beginDate":"2015-11-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-11-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"25C6CC93-326B-9598-E050-BB89AD436A4D","beginDate":"2015-11-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-11-30","modifiedBy":"ONEDATA","dateModified":"2015-11-30","deletedIndicator":"No"},{"value":"Myelodysplastic (MDS) / myeloproliferative (MPN) diseases","valueDescription":"Myelodysplastic Syndrome And/Or Myeloproliferative Neoplasm Disease or Disorder","ValueMeaning":{"publicId":"5057166","version":"1","preferredName":"Myelodysplastic Syndrome And/Or Myeloproliferative Neoplasm Disease or Disorder","longName":"5057166","preferredDefinition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001): Used to indicate that either or both of two items or options may be valid.: A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008): Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"And/Or","conceptCode":"C48928","definition":"Used to indicate that either or both of two items or options may be valid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Myeloproliferative Neoplasm","conceptCode":"C4345","definition":"A group of myeloid neoplasms that includes the following: chronic myeloid leukemia, BCR-ABL1 positive; polycythemia vera; essential thrombocythemia;  primary myelofibrosis; chronic neutrophilic leukemia; chronic eosinophilic leukemia, not otherwise specified; and myeloproliferative neoplasm, unclassifiable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"25C6CC93-3277-9598-E050-BB89AD436A4D","latestVersionIndicator":"Yes","beginDate":"2015-11-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-11-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"25C6CC93-3290-9598-E050-BB89AD436A4D","beginDate":"2015-11-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-11-30","modifiedBy":"ONEDATA","dateModified":"2015-11-30","deletedIndicator":"No"},{"value":"Acute myelogenous leukemia (AML)","valueDescription":"Acute Myeloid Leukemia","ValueMeaning":{"publicId":"4263972","version":"1","preferredName":"Acute Myeloid Leukemia","longName":"4263972","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise categorized. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63DCAA0-1110-5D4B-E040-BB89AD432C9C","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"KUMMEROA","dateModified":"2022-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"28217233-4EAF-A721-E050-BB89AD430EC3","beginDate":"2015-11-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-30","modifiedBy":"ONEDATA","dateModified":"2015-12-30","deletedIndicator":"No"},{"value":"Multiple myeloma / plasma cell disorder (PCD)","valueDescription":"Plasma Cell Myeloma","ValueMeaning":{"publicId":"2559811","version":"1","preferredName":"Plasma Cell Myeloma","longName":"2559811","preferredDefinition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Myeloma","conceptCode":"C3242","definition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B6B0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"25C6CC93-31DB-9598-E050-BB89AD436A4D","beginDate":"2015-11-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-11-30","modifiedBy":"ONEDATA","dateModified":"2015-11-30","deletedIndicator":"No"},{"value":"Chronic myelogenous leukemia (CML)","valueDescription":"Chronic Myelogenous Leukemia, BCR-ABL1 Positive","ValueMeaning":{"publicId":"2558495","version":"1","preferredName":"Chronic Myelogenous Leukemia, BCR-ABL1 Positive","longName":"2558495","preferredDefinition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and imatinib therapy delay disease progression and prolong overall survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3174","definition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B18C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"25C6CC93-31E5-9598-E050-BB89AD436A4D","beginDate":"2015-11-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-11-30","modifiedBy":"ONEDATA","dateModified":"2015-11-30","deletedIndicator":"No"},{"value":"Other malignant hematologic disorder","valueDescription":"Other Malignant Hematologic Disease or Disorder","ValueMeaning":{"publicId":"5210960","version":"1","preferredName":"Other Malignant Hematologic Disease or Disorder","longName":"5210960","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Refers to abnormal cell activity manifested by decreased control over growth and function, causing tumor growth or spread into surrounding tissue and adverse effects to the host.: Pertaining to or related to the blood and blood-forming organs.: Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Malignant","conceptCode":"C14143","definition":"Refers to abnormal cell activity manifested by decreased control over growth and function, causing tumor growth or spread into surrounding tissue and adverse effects to the host.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Hematologic","conceptCode":"C62780","definition":"Pertaining to or related to the blood and blood-forming organs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2FC1F18F-C9B2-E402-E050-BB89AD436C18","latestVersionIndicator":"Yes","beginDate":"2016-04-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-04-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2FC1F18F-C9CB-E402-E050-BB89AD436C18","beginDate":"2016-04-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-04-05","modifiedBy":"ONEDATA","dateModified":"2016-04-05","deletedIndicator":"No"},{"value":"Acute leukemia of ambiguous lineage and other myeloid neoplasms","valueDescription":"Acute Leukemia of Ambiguous Lineage And Other Myeloid Neoplasm","ValueMeaning":{"publicId":"5564775","version":"1","preferredName":"Acute Leukemia of Ambiguous Lineage And Other Myeloid Neoplasm","longName":"5564775","preferredDefinition":"An acute leukemia in which the blasts lack sufficient evidence to classify as myeloid or lymphoid or they have morphologic and/or immunophenotypic characteristics of both myeloid and lymphoid cells. (WHO, 2001): An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: Different than the one(s) previously specified or mentioned.: Diseases in which too many blood cells are made in the bone marrow.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Leukemia of Ambiguous Lineage","conceptCode":"C7464","definition":"An acute leukemia in which the blasts lack sufficient evidence to classify as myeloid or lymphoid or they have morphologic and/or immunophenotypic characteristics of both myeloid and lymphoid cells. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Myeloid Neoplasm","conceptCode":"C9290","definition":"Proliferation of myeloid cells originating from a primitive stem cell.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"406A4DBB-A3A3-2DEC-E053-F662850ACB9A","latestVersionIndicator":"Yes","beginDate":"2016-11-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-11-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4AC6DDFF-BB11-342F-E053-F662850A2C0E","beginDate":"2017-03-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-03-15","modifiedBy":"ONEDATA","dateModified":"2017-03-15","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5095331","version":"1","preferredName":"Malignant Hematologic Disease or Disorder Type","preferredDefinition":"Refers to abnormal cell activity manifested by decreased control over growth and function, causing tumor growth or spread into surrounding tissue and adverse effects to the host.:Pertaining to or related to the blood and blood-forming organs.:Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:Something distinguishable as an identifiable class based on common qualities.","longName":"C14143:C62780:C2991:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant","conceptCode":"C14143","definition":"Refers to abnormal cell activity manifested by decreased control over growth and function, causing tumor growth or spread into surrounding tissue and adverse effects to the host.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Hematologic","conceptCode":"C62780","definition":"Pertaining to or related to the blood and blood-forming organs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28217233-4DAC-A721-E050-BB89AD430EC3","latestVersionIndicator":"Yes","beginDate":"2015-12-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-30","modifiedBy":"ONEDATA","dateModified":"2015-12-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D3C0785-85D2-0279-E040-BB89AD4376C9","latestVersionIndicator":"Yes","beginDate":"2010-01-15","endDate":null,"createdBy":"WHITES","dateCreated":"2010-01-15","modifiedBy":"KUMMEROA","dateModified":"2017-03-15","changeDescription":". Added PV for 4000. AK 3/15/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685478","version":"1","longName":"Testing Set â€“ Moderately Different","context":"NCIP"}]}],"AlternateNames":[{"name":"CPRE_ICT_malig_hmt_ds_ty","type":"NMDP_FN","context":"NHLBI"},{"name":"definedObservation:nameCode","type":"HCT_BRIDG_5","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What is the malignant hematol","type":"Preferred Question Text","description":"What is the malignant hematologic disease or disorder?","url":null,"context":"NHLBI"},{"name":"Specify the malignant hematologic disorder","type":"Alternate Question Text","description":"Specify the malignant hematologic disorder","url":null,"context":"NHLBI"},{"name":"Specify the malignant hematologic disorder","type":"Application Standard Question Text","description":"Specify the malignant hematologic disorder","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D3C0785-863A-0279-E040-BB89AD4376C9","latestVersionIndicator":"Yes","beginDate":"2010-01-15","endDate":null,"createdBy":"WHITES","dateCreated":"2010-01-15","modifiedBy":"KUMMEROA","dateModified":"2021-08-23","changeDescription":"Added HCT_BRIDG5 alternate name - RR 2018-12-23","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}